Abstract
Existing methods for integrating functional annotations in GWAS to fine-map and prioritize potential causal variants are either limited to using non-overlapped categorical annotations, or limited by the computation burden of modeling genome-wide variants. To overcome these limitations, we propose a scalable Bayesian functional GWAS method to account for multivariate quantitative functional annotations (BFGWAS_QUANT), accompanied by a scalable computation algorithm enabling joint modeling of genome-wide variants. Simulation studies validated the performance of BFGWAS_QUANT for accurately quantifying annotation enrichment and improving GWAS power. Applying BFGWAS_QUANT to study five Alzheimer’s disease (AD) related phenotypes using individual-level GWAS data (n=∼1K), we found that histone modification annotations have higher enrichment than eQTL annotations for all considered phenotypes, with the highest enrichment in H3K27me3 (polycomb regression). We also found that cis-eQTL in microglia had higher enrichment than eQTL of bulk brain frontal cortex tissue for all considered phenotypes. A similar enrichment pattern was also identified using the IGAP summary-level GWAS data of AD (n=∼54K). The strongest known APOE E4 risk allele was identified for all five phenotypes and the APOE locus was validated using the IGAP data. BFGWAS_QUANT fine-mapped 32 significant variants from 1073 genome-wide significant variants in the IGAP data. We further demonstrated that the polygenic risk scores (PRS) using effect size estimates by BFGWAS_QUANT had similar prediction accuracy as other methods assuming a sparse causal model. Overall, BFGWAS_QUANT provides a useful GWAS tool for quantifying annotation enrichment and prioritizing potential causal variants.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
NIGMS/NIA
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
ROS/MAP and MCADGS data analyzed in this study were generated under the improvement by the Institutional Review Board (IRB) of Rush University Medical Center, Chicago, IL and Mayo Clinic, respectively. All samples analyzed in this study were de-identified and all analyses were approved by the IRB of Emory University School of Medicine.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors